Technicon Holding ApS

The Group's principal activity is the development, integration, and sale of advanced automation solutions for the global Life Science industry through its subsidiary, Technicon A/S. ​​The Parent Company's principal activity consists of holding shares in Technicon A/S and providing rental services

Development in activities and finances

The Group generated an operating profit of DKK 9,023 thousand and a profit after tax of DKK 6,253 thousand for the financial year, reflecting the continued operational performance of Technicon A/S. ​​Group equity amounted to DKK 20,614 thousand on April 30, 2026, compared with DKK 14,360 thousand on April 30, 2025. ​Management considers the financial performance for the year satisfactory and in line with the Group's strategic development.

The Group expects the coming financial year to be characterized by continued international commercial activity and the further development of new customer relationships through Technicon A/S. ​​Continued investments in standardized robotic solutions, digital technologies, and Artificial Intelligence are expected to strengthen operational efficiency, support productivity improvements across day-to-day operations, and enhance the Group's long-term competitiveness. ​​While the long-term outlook remains positive, Management expects the coming financial year to continue to be influenced by geopolitical uncertainty, cautious investment behavior, and general volatility in the global market. The Group will closely monitor market demand and continuously adapt its operational priorities and investment activities to reflect changing market conditions while maintaining a strong platform for future growth. The Group expects a positive result of maximum 5MDKK for the next coming year.

Profit/loss for the year in relation to expected developments

The Group has delivered a satisfactory financial performance during the year, supported by the continued operational development of Technicon A/S. ​​The result is higher than expected because the year has been characterized by strong project execution, continued investments in organizational development, quality, and international market activities. These initiatives support the Group's long-term strategy of strengthening its position within the global pharmaceutical industry while maintaining a solid operational and financial foundation. ​​Management considers the year's results to be satisfactory.

Recognition and measurement of work in progress are based on Management's assessment of the stage of completion of each individual project and the expected outcome of the remaining contractual obligations. ​​The estimates applied are subject to uncertainty, as the execution of projects depends on several factors, and project conditions may change during the completion process. Consequently, the final outcome of individual projects may differ from the estimates applied on April 30, 2026, resulting in both positive and negative deviations. ​​Recognition and measurement of development projects are likewise based on Management's assessment of each​project's progress and expected completion. The future development of these projects remains subject to changes in technical, commercial, and operational conditions that may affect the final outcome.

No events have occurred after the balance sheet date that materially affects the assessment of the Annual Report.

No events have occurred after the balance sheet date to this date, which would influence the evaluation ofthis​ ​annual report.

The Parent and the Danish subsidiaries participate in a Danish joint taxation arrangement in which serves as the ​administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Parent ​and the Danish subsidiaries are therefore liable for income taxes etc. for the jointly taxed entities,and also for ​obligations, if any, relating to the withholding of tax on interest, royalties and dividends for the jointly taxed ​entities. The jointly taxed entities' total known net liability under the joint taxation arrangement is disclosed in the​administration company's financial statements.​

19 Assets charged and collateral

As security for bank debt, a corporate mortgage has been made, which amounts to nominal DKK 16,000,000.​ ​​ ​The carrying amount of simple receivables, inventories, equipment and intellectual property rights, etc.​ ​amounts to DKK 62,473,277​​ ​Certain items of plant and machinery, and other fixtures etc have been financed by means of finance​ ​leases. The carrying amount of assets held under finance leases is DKK 729,429.​ ​

​ ​Mortgage debt is secured by way of mortgage on properties at a carrying DKK 5,414,683.​ ​Spar Nord Bank A/S also have a mortgage deed at DKK 2,300,000 in the properties at a carrying DKK 5,414,683.